David Esposito
Professional Overview
David Esposito is an accomplished business leader with extensive experience in the pharmaceutical and biotechnology industries. As the President and Chief Executive Officer of ONL Therapeutics, he leverages his deep expertise in commercial operations, strategic planning, and product development to drive the company's growth and impact. With a strong track record of success across various leadership roles, Esposito is well-equipped to navigate the complex challenges of the healthcare sector.
Experience Summary
Current Role
As the President and Chief Executive Officer of ONL Therapeutics since 2019, Esposito is responsible for the overall strategic direction and operational management of the company. Under his leadership, ONL Therapeutics has made significant strides in advancing its pipeline of innovative therapies, with a focus on unmet medical needs in ophthalmology. Esposito's strategic vision and collaborative approach have been instrumental in forging key partnerships and securing funding to support the company's research and development efforts.
Career Progression
Esposito's career has been marked by a progressive rise through the ranks of the pharmaceutical and biotechnology industries. Prior to joining ONL Therapeutics, he served as the President and Chief Executive Officer of Armune BioScience, Inc., where he led the company's successful acquisition by Exact Sciences Corporation. Esposito has also held various leadership roles at Merck, Phadia AB, and Thermo Fisher Scientific, where he demonstrated his expertise in commercial operations, strategic planning, and driving organizational growth.
Academic Background
Esposito holds a Bachelor of Science degree from the United States Military Academy at West Point, where he served as a Lieutenant in the 101st Airborne Division of the U.S. Army. His strong academic foundation and military training have instilled in him a disciplined approach to problem-solving and a commitment to excellence.
Areas of Expertise
Esposito's areas of expertise include:
- Commercial operations and strategic planning
- Product development and pipeline management
- Mergers and acquisitions
- Fundraising and investor relations
- Regulatory and compliance oversight
- Cross-functional team leadership and collaboration
Professional Impact
Throughout his career, Esposito has been recognized for his ability to drive transformational change and deliver tangible results. At Armune BioScience, he led the company's successful acquisition, which enhanced the company's reach and impact within the diagnostics industry. As a member of the Board of Directors at Allergenis and Hemotek, Esposito provides strategic guidance and oversight to support the growth and development of these innovative healthcare companies.
Conclusion
With a proven track record of success, David Esposito is a seasoned executive who is poised to continue making significant contributions to the pharmaceutical and biotechnology sectors. As the President and Chief Executive Officer of ONL Therapeutics, he is committed to leveraging his expertise to develop groundbreaking therapies and improve patient outcomes.
